EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Systemic Management of Advanced Adrenocortical Carcinoma

Jeffery S Russell

Current Treatment Options in Oncology · 2024

DOI: 10.1007/s11864-024-01249-6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, 2024. Verfasst von Jeffery S Russell. Beteiligte Einrichtung: Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, 84112, USA. jeffery.russell@hci.utah.edu. Hauptthemen laut MEDLINE: Adrenocortical Carcinoma, Disease Management, Adrenal Cortex Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OPINION STATEMENT: Adrenocortical cancer (ACC) is a rare and aggressive disease. Surgery has traditionally been the primary treatment for locally advanced disease with ongoing controversy around the optimal neoadjuvant and adjuvant treatment options. Unfortunately, local recurrence and the eventual development of metastatic disease is common and five-year survival rates are poor. While many trials have evaluated novel systemic agents to treat advanced adrenocortical cancer, only a few drugs have demonstrated any response at all. To date, only one drug, mitotane, is approved in the US for ACC and no regimen has clearly shown an increase in overall survival. In advanced metastatic or unresectable disease, data supports the first line regimen of EDP chemotherapy + mitotane as the primary treatment modality. In the second line, while data is limited, we would recommend consideration of immunotherapy using a PD(L)1 agent combined with a TKI/VEGF inhibitor or combination immunotherapy with PD1/CTLA-4 drugs. In all cases, we always prefer a clinical trial as available. This article reviews data from multiple studies evaluating novel systemic agents against ACC and discusses current systemic therapy combinations and ongoing clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenocortical CarcinomaDisease ManagementAdrenal Cortex NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNeoplasm StagingHumansCombined Modality TherapyMolecular Targeted TherapyTreatment OutcomeClinical Trials as Topic

Stichwörter der Autor:innen

Adrenal CancerAdrenocortical CancerMetastasisSystemic Therapy

Autor:innen und Institutionen

  • Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, 84112, USA. jeffery.russell@hci.utah.edu.

Zitieren

APA

Russell, J. S. (2024). Systemic Management of Advanced Adrenocortical Carcinoma. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-024-01249-6

Vancouver

Russell JS. Systemic Management of Advanced Adrenocortical Carcinoma. Current Treatment Options in Oncology. 2024. doi:10.1007/s11864-024-01249-6

BibTeX
@article{Russell2024,
  author = {Russell, Jeffery S},
  title = {Systemic Management of Advanced Adrenocortical Carcinoma},
  journal = {Current Treatment Options in Oncology},
  year = {2024},
  doi = {10.1007/s11864-024-01249-6}
}
Kostenlos starten →